What Inane Nonsense is Cytodyn Hyping Now? (CYDY)

It never seems to stop. Another day, more nonsense from everyone’s favorite reverse merger pink sheet Coronacrapper, Cytodyn (CYDY). So just what is Cytodyn hyping today?

After the bell last night, on the 7th of June, the company issued the latest in a long series of breathless press releases (here) touting, this time, an animal study. Eighteen (18) rhesus macaques were given Cytodyn’s “wonder drug” leronlimab and then deliberately infected with SHIV (aka Monkey AIDS) in an intrarectal challenge (aka up the butt). And what do you know? One of the two doses studied seemed to be effective in preventing the transmission of the Monkey AIDS (hard to say for sure, as there was no control group and n=18 is too small to make valid determinations, but hey, this is CYDY, where it’s all about the press releases to keep American and German retail morons excited). Great news for macaques? Not really. Because just a year ago a study was published on a vaccine that keeps macaques safe from infection by SHIV (here).

But The Nadir won’t tell you about that, because the point of press release is to get the retail base excited about the idea of using leronlimab as “PrEP” (Pre-Exposure Prophylactic) for human AIDS. Currently the approved PrEP regimen is a well known combination pill known as Truvada. Cytodyn is trying to hype up the idea of using a weekly or bi-monthly injection of leronlimab instead. Said The Nadir:

“We are eager to build upon these preclinical results describing leronlimab’s utility in HIV prevention by initiating clinical studies for leronlimab as a PrEP treatment. Current PrEP options require a continued daily dosing regimen in order to be effective and are inherently difficult to maintain in the long-term,” said Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn. “Coupled with its safety profile, leronlimab could offer a much needed simple and long-lasting preventative treatment option for people at risk of HIV infection,” concluded Dr. Pourhassan.

It is all just warmed-over nonsense, of course, as The Nadir has been doing this since at least 2013! Remember this press release?

(more…)

Quick Take – Who’s “Distributing” Cytodyn’s “Wonder Drug” Now? (CYDY)

Spolier alert: Actually no-one because Cytodyn does not have any marketable products but if they did….

What a way to start the week, the long awaited “Distribution Agreement” news has finally been released by everyone’s favorite reverse merger pink sheet Coronacrapper, Cytodyn (CYDY).

Readers might recall that on June 2, 2020 The Nadir had this to say:

Distribution-June-2

OK, a non-binding term sheet “with a pretty well known company.” Sounds like absolutely nothing. And on June 11th, The Nadir and Mike Mulholland provided this update:

Cytodyn-distribution-june-11

And now, today July 6th, 2020 we get the big reveal. Just who is lucky enough to “distribute”* Cytodyn’s wonder drug, leronlimab?

CYDY-AmericanRegent

American Regent! Surely a “pretty well known company”. Never heard of them? Prior to 2019 they were known as Luitpold Pharmaceuticals. Never heard of them? Well you might know them from their previous incarnation as Luitpold-Werk. No?

Although the details are few, it appears to be a deal with zero risk for American Regent. Until and unless leronlimab gets an EUA or an approval for Covid-19, there is nothing to distribute. There appear to be no commitment, and American Regent doesn’t get a standard distribution mark-up, they actually get a profit split. The bidding over leronlimab must have been INTENSE.

A quick perusal of the American Regent web site shows they are a distributor of mundane IV vitamin and minerals (31 different SKUs mostly different dosages of a few products) and a few low value generic drugs. (36 SKUs, most just different dosages of a few products).

One thing that DOES make American Regent a perfect partner for Cytodyn, however, is this curious section of their website, devoted to their distribution of products UNapproved by the FDA! Surely a perfect match.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

 

Quick Take – Who’s Grossly Overexaggerating Cytodyn’s TAM Now? (CYDY)

Another day, another relentlessly “optimistic” piece of promotional garbage touting everyone’s favorite Pink Sheet Reverse Merger coronacrapper, Cytodyn (CYDY). Today it is this swill which trumpeted an outlandish TAM (Total Addressable Market) figure that whipped up retail investors on both sides of the Atlantic this morning, before reality began to seep back in. How outlandish? See for yourselves:

Cytodyn TAM (in their dreams)

Yes, $81bn, but that’s not all, maybe even $100bn!

Now for the sobering reality. Cytodyn has exactly zero approved drugs to sell. Zero. After much difficulty they have submitted a BLA to the FDA, to hopefully get their wonder drug, leronlimab, approved in early 2021. Guess that $81bn won’t come this year, if at all.

But even if they get their drug approved, the actual TAM is far far smaller. For you see, dear reader, leronlimab is what is known as a “CCR5 Entry Inhibitor“, and one that must be delivered by IV or injection. There already is a another CCR5 entry inhibitor on the market, known generically as maraviroc, or by its brand name, Selzentry. Unlike the hyped unapproved bullshit from Cytodyn, maraviroc is a convenient pill, available today.

Contrary to anything the long list of promoters, or even The Nadir, might claim, leronlimab is not a new class of medication, it is not a breakthrough, it is just another entry in an existing segment.

And how large is the Total Addressable Market for CCR5 Entry Inhibitors? Currently maraviroc has 100% of that market, and it was, for 2019 a paltry $88mm USD and SHRINKING.

TAM-Chart

Even if leronlimab magically captured 100% market share, $88mm is still only about 7/10ths of a percent of the supposed $12bn HIV TAM. Good luck with that $81bn!

Oh, and coronavirus? If CCR5 entry inhibition had anything to do with Coronavirus, Doctors world-wide would already be using maraviroc. Surprise! They aren’t. 

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

How Can Franklin J. Schaffner’s Masterpiece Help Investors?

From the 29th Scroll, 6th Verse:

“Beware the reverse merger, for it is the devil’s pawn. Alone among listed stocks it exists as shells, or SPACs, or stubs. Yea, it will jump on any trend to excite and possess the masses’ cash. Let them not list in great numbers, for they will make a mockery of exchanges and regulators. Shun them. Drive them back into their bucket shop lairs, for they are the harbingers of massive losses.”

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

Quick Take: Who is Getting A Big Raise At Cytodyn Now? (CYDY)

Just a month after selling a multi-million dollar boatload of stock, Coronacrapper Cytodyn (CYDY) CEO Nader “The Nadir” Pourhassan just scored a massive raise.

After the bell last night, Cytodyn issued an 8k (see here) disclosing an almost 100% increase in Nader’s base compensation to $1mm:


He wasn’t doing too badly in prior years either:

Of course on his rambling call with stock promoter Jacob Mestechkin aka Jack Marks yesterday, this was never mentioned. 

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

QUICK TAKE: Who Else Used a Cashless Exercise of his Cytodyn Options? (CYDY)

After the bell last night a Form 144 filing (available here) was released concerning everybody’s favorite pink sheet bioturd, the Creme de la Creme of Coronacrappers, Cytodyn (CYDY).
ScottKelly144-WSA
In this one, Scott Kelly, the Chairman of the company (who unlike two of his predecessors is not suing the company – yet) details not only his sale of 1.2mm shares that we discussed last week here, but also how he paid for the shares. Hint: Not with any cash going to the company.
ScottKelly-Cashless
That’s right, contrary to CEO Nader “The Nadir” Pourhassan’s bizarre explanations that he and Scott sold the stock to somehow fund the company (and SAVE LIVES! with magic leronlimab), Scott used the same cashless exercise feature that The Nadir employed. Something of a feather something together…

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

Who’s Preposterously Defending & Touting Cytodyn Now (Hint: An Actual Felon)? (CYDY)

It’s been a busy two weeks for everyone’s favorite retail owned pink sheet coronacrapper Cytodyn. As you may recall Cytodyn has been hyping its ancient CCR5 targeted antibody, leronlimab, for ages. As an AIDS cure, a cancer cure, and now, of course, a Coronavirus cure. All the while its retail shareholder base believes they are part of actively building a bright new future and SAVING LIVES!

Some of the stock promoters pushing this long running joke were exposed (here). Then large shareholders sued the company (here). Soon after, lots of insider sales were revealed (here and here and here).

Then CEO extraordinaire Nader “The Nadir” Pourhassan, made up some amazing baloney about why he sold stock (see STAT News article here). Finally, he was caught lying in his April 27th announcement about CYDY‘s long awaited BLA submission being completed (read about that in a STAT News article here).

The company and its paid shills have not been standing still, however. The Nadir’s hypsters have come out to support their beleaguered boss with more and more “imaginative” defenses of the company and the CEO’s actions.

One such piece recently appeared on a website called EmergingGrowth.com (a site which has promoted Galectin (GALT) in the past as well, which seems to be a common co-morbidity). This piece makes up wild accusations against Adam Feuerstein, the reporter at Stat News, and makes the silly claim that Cytodyn’s collection of anecdotes somehow constitute real clinical trial data (hint: the plural of anecdote is not data).

It also seeks to brush aside Cytodyn’s failure to include the complete clinical dataset for leronlimab in its April 27th BLA submission.

“The focus on “clinical datasets” is akin to someone making a mountain out of a molehill”

Recall that the company actually submitted “mock datasets” to the FDA.

“The clinical datasets are updated to address FDA comments for mock datasets from March 12 and March 20, 2020,”

For intellectually challenged CYDY shareholders, the definition of mock is:

mock

Contrary to the suggestion that it was a meaningless oversight, the most important part of any approval submission to the FDA is the clinical data!

Only buried deep in the EmergingGrowth.com website will you find this disclaimer, revealing that it is nothing but a paid stock promotion website.

EmergingGrowthCYDYDisclosure1

And what could this “additional compensation” be?

CYDY-EmegingDisc2

The EmergingGrowth tout piece references a piece on yet another site, Medical News First. This site parrots the absurd claims of The Nadir that he somehow sold personal stock to fund production of Cytodyn’s snake oil, instead of having the company sell stock or take out a loan, or pay for the production in shares, or do anything else that real companies do to pay the bills.

MN1-CYDY

Instead, it is a selfless act to save lives! The piece winds down with this howler:

Dr. Pourhassan is a national hero, not a villain.  His motivation was to save lives and prevent shareholder dilution.  In fact, his selfless insider sales are tantamount to a $15.0+ million bet that this drug works and is going to be approved in short order.

Of course, the theory that the shills have been pushing, that The Nadir exercised his options to provide cash to the company to fund production of the magic snake oil, is obviously untrue. Nader used the cashless exercise feature of his options, meaning that no cash went into the company’s coffers, but plenty went into The Nadir’s bank account. From the Form 144:

CYDY-CashlessExercise

Interestingly, nowhere on the Medical News First page is any disclaimer. Does this mean Medical News First is legit? Actually, no. Not in the least.

Follow the link in the upper right hand corner of the Medical News First page, and you will end up on the MN1.com site, with that same Cytodyn puff piece featured:

mn10cydy2

Digging deeper, it turns out that MN1.com is yet another stock promotion vehicle, offering paid promotion disguised as “news”. Pick your plan:

MN1-Pricing

Although there is still no actual disclosure. Which plan did Cytodyn (or one of its backers) pick? How much was paid to MN1.com to promote CYDY shares? And who is behind MN1? For now we can only answer the latter question. An entity called Lankford Media.

WhoIsMN1

Who is Lankford Media?

LankfordmediaFB

Two brothers, Gary and Joshua Lankford. And now for the payoff. Who is Joshua Lankford? A barred broker

LankfordCRD

convicted and sentenced for his role in a pump and dump ring.

Lankford-Sentence

Now an ex-con

BOP-Lankford

Here is Lankford doing a Cytodyn promotional video from early March 2020.

Mr. Lankford seems to be very fond of promoting Cytodyn without the proper disclosure, which is especially odd considering he should not be promoting CYDY shares at all, given the court order in his case:

LankfordSECBar

As for actively building a bright new future and SAVING LIVES, Cytodyn shareholders will only learn that they are being passively fleeced in the mundane present.

PS: Lankford also is behind the almost identical marketnewsfirst.com website.

marketnewsfirstwhois

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

Quick Take: Who ALSO Sold Cytodyn Stock Last Week? (CYDY)

After the bell last night a Form 4 filing (see last week’s infamous Form 144 filing here) was released concerning everybody’s favorite pink sheet bioturd, the Creme de la Creme of Coronacrappers, Cytodyn (CYDY).

ScottKelly

First the CEO Nader “The Nadir” Pourhassan dumped a bunch of stock starting on the 30th of April, with an absolutely insane explanation (more on that soon, but start here), then the CMO, Scott Kelly let loose 1.2mm shares on the 1st of May. Taking advantage of severe cases of Coronamania among stuck at home retail investors both in the USA and Germany seems to be the new normal among bioturds and their execs.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

 

Who ELSE is Selling Cytodyne Stock Now? (CYDY)

After the bell today a Form 144 filing (get it here in the April 30 link) was released concerning everybody’s favorite pink sheet bioturd, Coronacrapper extraordinaire, Cytodyn (CYDY).

1175680 CytoDynInc NaderPourhassan 20200430

CYDY=144

Yes, CEO Nader “The Nadir” Pourhassan sold 4.8mm shares on 30 April, while telling the world the amazing wonders of Cytodyn‘s ancient one time AIDS-then cancer-now-coronavirus drug. Said the company that day:

(more…)

Who’s Selling Cytodyn Stock Now? (CYDY)

Last night, as April came to a close, pink sheet Coronacrap stock, Cytodyn (CYDY), a favorite of retail investors both in the USA and Germany (Freut mich), released an amended S3 filing with the SEC. (Catch up on Who’s Touting Cytodyn Now and Who’s Suing Cytodyn Now too)

This filing will allow for millions of shares to be dumped on the market. How many millions?

(more…)